Researchers put gingko on trial for treatment of dementiaAugust 19, 2004Researchers in London are to explore the effectiveness of gingko, a complementary medicine traditionally used to treat circulatory problems, as a treatment for early dementia. The study of 250 patients aged over 55 will seek to find out whether GPs can help patients by prescribing the supplement to those with memory loss, one of the early symptoms of dementia. It will be the first to test gingko as a treatment for those who are still living in the community and are being treated by their GP. Previous trials have concentrated on patients receiving hospital care, where the condition is often more advanced. "We believe gingko may prove more effective if prescribed in a community setting, where patients' symptoms are usually less severe," says Dr James Warner, a psychiatrist from Imperial College London and St Mary's Hospital, who is leading the study. "This trial will help us to find out whether with gingko it's a case of 'the sooner the better', for patients who may benefit from taking it." Gingko is believed to cause blood vessels to dilate, improving blood flow to the brain, and to thin the blood, making it less likely to clot. Gingko may also have antioxidant effects, protecting nerve cells against biological 'rusting'. "All of these effects would suggest that gingko might slow down a degenerative process such as dementia," says Dr Warner. It is estimated that 700,000 people in the United Kingdom are affected by the condition, 60 per cent of whom are diagnosed with Alzheimer's disease. Patients might occasionally misunderstand who or where they are, forget people's names or how to get home. Gingko could provide a cheaper alternative to conventional medicines, with fewer of the potential side effects such as nausea, loss of appetite, tiredness and diarrhoea. A quality gingko extract taken from the Gingko biloba tree costs around £200 for a year's supply. It is currently available over the counter in the UK, most European countries and the United States. Conventional medicines for memory loss are based upon a class of drugs known as cholinesterase inhibitors, which cost around £1,000 a year, and prescription of these drugs is restricted. Some patients also benefit from therapies such as music therapy, aromatherapy and reminiscence therapy, which keep the environment stimulating and encourage the use of the brain. Participants on the double-blind trial will continue to take their conventional medicines for age-associated memory loss. For six months they will be given 60mg of gingko extract or a placebo twice daily. Participants will also receive up to three visits of one and a half hours where researchers will examine each individual's cognitive functioning, their memory, quality of life and behaviour. Robert McCarney, research associate on the study adds "We are now recruiting individuals living in or around London and the home counties, aged over 55 and whom their GP suspects may have dementia. Anyone interested in finding out more about the study should telephone 020 7886 7697". For general information relating to age-associated memory loss or Alzheimer's disease, contact The Alzheimer's Society helpline on 0845 300 0336. The study is being carried out by Imperial College London in collaboration with the London School of Hygiene and Tropical Medicine, the Royal London Homeopathic Hospital and University College London. The Alzheimer's Society is funding the research. Gingko facts *Fossilised remains of the ancient tree have been found dating back 200 million years. | |||||||||||||||||||||
|
Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. Study confirms benefit of combination therapy for Alzheimer's disease Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ability to perform daily activities. Seniors with type 2 diabetes may experience memory declines immediately after eating unhealthy meal Adults with type 2 diabetes who eat unhealthy, high-fat meals may experience memory declines immediately afterward, but this can be offset by taking antioxidant vitamins with the meal, according to new research from Baycrest. Memory loss linked to common sleep disorder For the first time, UCLA researchers have discovered that people with sleep apnea show tissue loss in brain regions that help store memory. Strong associations between disturbed rest/activity rhythms and mortality rates in older men A research abstract that will be presented on Wednesday at SLEEP 2008, the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS), is the first to report strong associations between disturbed rest/activity rhythms and mortality rates in older, community-dwelling (non-institutionalized) men. Hopkins researchers discover new link to schizophrenia Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors. A significant difference in the sleep disturbances among Alzheimer patients, caregivers A study published in the May 1 issue of the journal SLEEP finds that sleep disturbances among Alzheimer patients vary significantly from those of their family caregivers, and that, surprisingly, poor sleep in either the patient or caregiver is not necessarily linked to disturbed sleep in the other. Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment A promising vaccine being tested for Alzheimer's disease does what it is designed to do - clear beta-amyloid plaques from the brain - but it does not seem to help restore lost learning and memory abilities, according to a University of California, Irvine study. Why fish oil is good for you It's good news that we are living longer, but bad news that the longer we live, the better our odds of developing late-onset Alzheimer's disease. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||